In light of the significant drop in Regeneron’s stock price, a natural question emerges: is REGN now a viable buying ...

TD Cowen analyst Tyler Van Buren maintained a Buy rating on Regeneron (REGN – Research Report) today and set a price target of $1,030.00. The company’s shares closed yesterday at $686.33.

View the latest REGN financial statements, income statements and financial ratios. Regeneron Pharmaceuticals Inc. Annual stock financials by MarketWatch. Skip to main content ...

Barclays analyst Carter Gould maintained a Buy rating on Regeneron (REGN – Research Report) today and set a price target of $1,220.00. The company’s shares closed last Friday at $1,042.69.